Regenesis Bio Expands Leadership Team

Regenesis Biomedical Expands Payor Sources to Increase Patient Access  with addition of a new Reimbursement and Health Economics Vice President and Expands Leadership Team and Market Reach with a new COO.

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

January has been a time of growth and leadership expansion for 2011 AZBio Fast Lane Award Winner Regenesis Biomedical, Inc. with the addition of new memners of the leadership team.

On January 9, 2012, Regenesis Biomedical, Inc., a medical technology company that markets the Provant® Therapy System, announced that  William (Bill) Gittinger joined the company as Vice President of Reimbursement and Health Economics. In this new role, Bill is chartered with securing expanded payor sources for the Provant Therapy System. Primary emphasis is on Medicare, Medicaid and commercial payors. He is also responsible for demonstrating the cost-effectiveness of the therapy, to increase payor and clinician adoption.

Bill gained relevant experience in leadership positions with Genzyme, Smith & Nephew, Baxter Healthcare and Bionicare. He has a proven track record of developing contracts with payors, public and private, as well as a thorough understanding of clinical and economic data, coding, coverage and payment processes. “We are pleased Bill is joining us to develop and execute our global reimbursement strategies,” said Virginia Rybski, President and CEO of Regenesis. “His background complements the management team, and he will work closely with them as we build our expanded reimbursement capabilities.”

Bill graduated from the University of Cincinnati, McMicken College of Arts & Science with a bachelor’s degree in biology. He is a certified member of AAPC, the American Association of Professional Coders, and a member of AdvaMed and will represent Regenesis in their Payment Advisory Work Group.

Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer

Regenesis Biomedical, Inc. announced on January 16, 2012 that Scott Brooks has joined the company in the newly created position of Chief Operating Officer. Scott is responsible for helping scale the organization’s capabilities to support increased market penetration and broadened reimbursement.

Most recently Scott was President of sales, marketing and customer service at BSN Medical located in Charlotte, NC. He led a team of 190 people in the US and Canada. Prior to that, Scott was the VP of Sales and National Accounts at Kinetic Concepts Inc. (KCI), the marketer of the wound VAC. At KCI he managed a team of sales and national accounts professionals who sold advanced wound care, critical care, and bariatric care devices in the US to hospitals, nursing homes, and homecare. Scott served on the KCI management team as the company emerged into a global leader. His experience includes successful leadership positions with The Hill-Rom Company, Kimberly Clark Health Care, and Covidien. “Scott is a mission focused, strategic, and process minded leader with experience scaling an organization,” said Virginia Rybski, President and CEO of Regenesis. “We look forward to his contributions in building upon our performance based culture.”

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

About the Provant® Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

 

Contact: Regenesis Biomedical, Inc.
Scott Robey, Vice President Marketing

www.regenesisbio.com

480-970-4970 phone

SOURCE: Regenesis Biomedical Inc.

Posted in AZBio News, Members and tagged , , .

Leave a Reply